Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LXN Hopes To Stay In Charge of Diabetes Control Market With $57.5 Mil. IPO

This article was originally published in The Gray Sheet

Executive Summary

LXN's agreement to supply Bristol-Myers Squibb with the company's In Charge for expanded indications of the diabetes drug Glucovance will translate into greater sales of the home glucose monitoring system, according to an Oct. 16 initial public offering prospectus filed with the Securities and Exchange Commission.
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT014047

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel